Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Moodys
US Department of Justice
Johnson and Johnson
Accenture
Fish and Richardson
Healthtrust
Covington
McKesson

Generated: October 22, 2018

DrugPatentWatch Database Preview

Glaxo Grp England Company Profile

« Back to Dashboard

What is the competitive landscape for GLAXO GRP ENGLAND, and when can generic versions of GLAXO GRP ENGLAND drugs launch?

GLAXO GRP ENGLAND has one approved drug.

There are ten US patents protecting GLAXO GRP ENGLAND drugs.

Summary for Glaxo Grp England
US Patents:10
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Glaxo Grp England

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,161,968 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,201,556 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,309,572 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 7,498,440 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 9,333,310 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,746,242 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Glaxo Grp England Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014038,C1740177 Lithuania ➤ Try a Free Trial PRODUCT NAME: UMEKLIDINO BROMIDAS; REGISTRATION NO/DATE: EU/1/14/922 20140428
90060-9 Sweden ➤ Try a Free Trial PRODUCT NAME: UMECLIDINIUM BROMIDE; REG. NO/DATE: EU/1/14/922 20140428
1740177/03 Switzerland ➤ Try a Free Trial PRODUCT NAME: UMECLIDINIUM BROMID; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
2014 00052 Denmark ➤ Try a Free Trial PRODUCT NAME: UMECLIDINIUMBROMID; REG. NO/DATE: EU/1/14/922/001-003 20140428
8 50012-2014 Slovakia ➤ Try a Free Trial PRODUCT NAME: UMEKLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001 - EU/1/14/922/003 20140430
C0075 France ➤ Try a Free Trial PRODUCT NAME: BROMURE D'UMECLIDINIUM; REGISTRATION NO/DATE: EU/1/14/922 001-003 20140428
2014000096 Germany ➤ Try a Free Trial PRODUCT NAME: UMECLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Citi
Mallinckrodt
Queensland Health
Accenture
Cantor Fitzgerald
Farmers Insurance
UBS
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.